Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Top R&D Stories of 2023
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Immunotherapy (Non-Oncology)
Treating Autoimmune Diseases: Past, Present, and Future
Bringing together the experts to discuss the timeline of autoimmune disease therapeutics.
Tumour Microenvironment
Tackling Solid Tumours in Immuno-Oncology
What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?
Drug Discovery & Development
Targeting Solid Tumours With TCR Guided NK Cells
Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy
Immuno-Oncology
Better IO Clinical Trials with ImmunoPET Imaging
Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.
Immuno-Oncology
Search and Destroy: Engineering T-Cells to Find and Kill Cancer
Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.
Biomarkers & Precision Medicine
Three Leading Perspectives on Biomarker Diagnostic Discovery in Immuno-oncology
Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.
Immunotherapy (Non-Oncology)
Insights in Autoimmunity and Immunotherapy
Experts discuss elusively successful therapies and the rising costs that come with new technologies.
Immunotherapy (Non-Oncology)
Re-Educating the Immune System: a ‘Brave New World’ in Immunology
RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field.
Immuno-Oncology
Multi-Specific Protein Modalities For Solid Tumours
An interview with Rajika Perera, Chief Executive Officer, Poseidon Laboratory